SNDX Insider Trading

Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $25,037.50
Insider Selling (Last 12 Months): $336,086.50

Syndax Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Syndax Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$336ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Syndax Pharmaceuticals Share Price & Price History

Current Price: $13.18
Price Change: Price Decrease of -0.38 (-2.80%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for SNDX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$13.18Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Syndax Pharmaceuticals (NASDAQ:SNDX)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SNDX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$126Mbought$170MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M$0$100MTotal InflowsTotal Outflows
Syndax Pharmaceuticals logo
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Read More on Syndax Pharmaceuticals

Today's Range

Now: $13.18
Low: $12.95
High: $13.80

50 Day Range

MA: $14.30
Low: $12.53
High: $16.38

52 Week Range

Now: $13.18
Low: $12.06
High: $25.07

Volume

913,539 shs

Average Volume

1,509,227 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Who are the company insiders with the largest holdings of Syndax Pharmaceuticals?

Syndax Pharmaceuticals' top insider investors include:
  1. Michael A Metzger (CEO)
  2. Keith A Goldan (CFO)
  3. Neil Gallagher (Insider)
  4. William Meury (Director)
  5. Briggs Morrison (Director)
Learn More about top insider investors at Syndax Pharmaceuticals.

Who are the major institutional investors of Syndax Pharmaceuticals?

Syndax Pharmaceuticals' top institutional investors include:
  1. Vanguard Group Inc. — 5.72%
  2. Wellington Management Group LLP — 4.96%
  3. Wellington Management Group LLP — 4.92%
  4. Soleus Capital Management L.P. — 2.92%
  5. Avoro Capital Advisors LLC — 2.67%
  6. Assenagon Asset Management S.A. — 2.42%
Learn More about top institutional investors of Syndax Pharmaceuticals stock.

Which major investors are selling Syndax Pharmaceuticals stock?

During the previous quarter, SNDX stock was sold by these institutional investors:
  1. Eversept Partners LP
  2. Avoro Capital Advisors LLC
  3. Marshall Wace LLP
  4. Avidity Partners Management LP
  5. Wellington Management Group LLP
  6. Wellington Management Group LLP
  7. Bank of America Corp DE
  8. Millennium Management LLC
During the previous year, company insiders that have sold Syndax Pharmaceuticals company stock include:
  1. Michael A Metzger (CEO)
  2. Keith A Goldan (CFO)
  3. Neil Gallagher (Insider)
Learn More investors selling Syndax Pharmaceuticals stock.

Which major investors are buying Syndax Pharmaceuticals stock?

During the previous quarter, SNDX stock was bought by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. Soleus Capital Management L.P.
  3. Octagon Capital Advisors LP
  4. Renaissance Technologies LLC
  5. Trexquant Investment LP
  6. Altium Capital Management LLC
  7. Cubist Systematic Strategies LLC
  8. Sphera Funds Management LTD.